Consistent with the present findings, significantly reduced serum levels of biologically active TGF-β1 were observed during exacerbation of MS [50], and lower levels of TGF-β1 were shown in RRMS compared to healthy subjects [51]. The gene discussed is TGFB1; the disease is myeloid sarcoma.